[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Akamatsu S, Kanamaru S, Ishihara M, Sano T, Soeda A, Hashimoto K: Primary large cell neuroendocrine carcinoma of the urinary bladder. Int J Urol; 2008 Dec;15(12):1080-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary large cell neuroendocrine carcinoma of the urinary bladder.
  • Large cell neuroendocrine carcinoma (LCNEC) of the urinary bladder is rare.
  • It is a type of neuroendocrine carcinoma morphologically distinct from small cell carcinoma.
  • We report here a case of primary LCNEC of the urinary bladder.
  • We observed a very large invasive tumor, which was not able to be detected three months previously by cystoscopy or computed tomography.
  • With prompt cystoprostatectomy and chemotherapy, the patient is free of disease 16 months after diagnosis.
  • Although LCNEC is usually very aggressive, it may be controlled by early diagnosis and treatment.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Urinary Bladder / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19120517.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


2. Ismaili N, Ghanem S, Mellas N, Afqir S, Taleb M, Amrani M, Gamra L, Errihani H: Small cell carcinoma of the urinary bladder: a case report and review of the literature. J Cancer Res Ther; 2009 Apr-Jun;5(2):133-6
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the urinary bladder: a case report and review of the literature.
  • Small cell carcinoma of the bladder (SCCB) is extremely rare.
  • In this paper, we present a case of metastatic SCCB managed by chemotherapy and we would provide a brief review of the epidemiology, clinical features, diagnosis, pathologic features, staging, treatment, and prognosis of SCCB.
  • A 52-year-old man was admitted with signs and symptoms suggestive of a bladder cancer.
  • Computed tomography of the pelvis and abdomen showed a large tumor at the right bladder wall, measuring 10 cm in diameter, and a multinodular liver disease.
  • Diagnosis of small cell carcinoma was established from the histological study of the transurethral resection of the bladder tumor.
  • The patient received 12 cycles of platinum-based chemotherapy with a good partial response of bladder tumor and liver metastasis.
  • The patient is still alive, 18 months after diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542673.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Ide H, Nakajima Y, Horinaga M, Shinojima T, Ozu C, Hatakeyama N, Kiguchi H: [Bladder carcinoma metastases presenting as intraperitoneal dissemination without local recurrence: a case report]. Nihon Hinyokika Gakkai Zasshi; 2004 Nov;95(7):813-6
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder carcinoma metastases presenting as intraperitoneal dissemination without local recurrence: a case report].
  • Cystoscopy showed broad-based papillary tumors on the left bladder wall.
  • TUR-BT was performed and pathological diagnosis was grade 3 transitional cell carcinoma of pT1a.
  • Although no intravesical tumor recurrence had been observed, a solid palpable mass was noted in the lower abdomen nine months after TUR-BT, and computed tomography suggested a large ovarian tumor.
  • Subsequently performed was the operation at Gynecology, which revealed a large tumor involving the whole major omentum.
  • Frozen sections of the tumor were diagnosed as transitional cell carcinoma metastases of the bladder cancer, and the final pathological report was the same.
  • Although receiving 4 courses of M-VAC systemic chemotherapy after the operation, she died 14 months later.
  • Autopsy disclosed intraperitoneal cancer dissemination and metastases without any intravesical nor left perivesical tumor recurrence, and it was suggested that the bladder tumor metastases occurred not by direct invasion but by either lymphatic or vascular mechanism in this case.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Neoplastic Cells, Circulating / pathology. Peritoneal Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15624492.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Earel JK Jr, VanOosten RL, Griffith TS: Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res; 2006 Jan 1;66(1):499-507
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
  • Urothelial carcinoma of the bladder accounts for approximately 5% of all cancer deaths in humans.
  • The large majority of tumors are superficial at diagnosis and, after local surgical therapy, have a high rate of local recurrence and progression.
  • Current treatments extend time to recurrence but do not alter disease survival.
  • The objective of the present study was to investigate the tumoricidal potential of combining the apoptosis-inducing protein tumor necrosis factor-related apoptosis inducing ligand (TRAIL) with histone deacetylase inhibitors (HDACi) against TRAIL-resistant bladder tumor cells.
  • Pretreatment with HDACi at nontoxic doses, followed by incubation with TRAIL, resulted in a marked increase in TRAIL-induced apoptosis of T24 cells but showed no significant increase in toxicity to SV40 immortalized normal human uroepithelial cell-1.
  • The increased TRAIL-R2 levels also resulted in accelerated death-inducing signaling complex (DISC) formation, caspase activation, and loss of mitochondrial membrane potential, which all contributed to the increase in tumor cell death.
  • Collectively, these results show the therapeutic potential of combining HDAC inhibition with TRAIL as an alternative treatment for bladder cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis Regulatory Proteins / pharmacology. Histone Deacetylase Inhibitors. Membrane Glycoproteins / pharmacology. Tumor Necrosis Factor-alpha / pharmacology. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Apoptosis / physiology. Caspases / metabolism. Cell Line, Tumor. Drug Synergism. Enzyme Inhibitors / administration & dosage. Enzyme Inhibitors / pharmacology. Humans. Intracellular Membranes / drug effects. Intracellular Membranes / physiology. Membrane Potentials / drug effects. Membrane Potentials / physiology. Mitochondria / drug effects. Mitochondria / physiology. Receptors, TNF-Related Apoptosis-Inducing Ligand. Receptors, Tumor Necrosis Factor / biosynthesis. Receptors, Tumor Necrosis Factor / genetics. Receptors, Tumor Necrosis Factor / metabolism. TNF-Related Apoptosis-Inducing Ligand. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16397266.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA109446
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Membrane Glycoproteins; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10B protein, human; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; EC 3.4.22.- / Caspases
  •  go-up   go-down


5. Izquierdo L, Truán D, Alvarez-Vijande R, Alcaraz A: [Large series of 114 cases with long-term follow-up of upper urinary tract urothelial tumors]. Actas Urol Esp; 2010 Mar;34(3):232-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Large series of 114 cases with long-term follow-up of upper urinary tract urothelial tumors].
  • [Transliterated title] Carcinoma urotelial de tracto urinario superior: 114 casos con largo seguimiento.
  • PURPOSE: Upper urinary tract urothelial carcinoma (UUTUC) represents 5% of all urothelial tumors and has uncertain prognostic.
  • Variables analyzed were age, sex, pathological tumor stage, histological tumor grade, CIS, tumor localization, multiplicity, bladder cancer history, pathological nodes and adjuvant chemotherapy.
  • Fifteen patients presented pathological nodes at the moment of diagnosis.
  • Fourteen percent of 114 patients received adjuvant treatment (Platin-based regimen).
  • Mean follow-up: 74.8 months; 30.7% of the patients developed tumor progression.
  • Mean time of tumor progression: 12.2 months and 23.3 months for cancer-specific death.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Nephrectomy. Ureteral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20416239.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


6. Lee KH, Ryu SB, Lee MC, Park CS, Juhng SW, Choi C: Primary large cell neuroendocrine carcinoma of the urinary bladder. Pathol Int; 2006 Nov;56(11):688-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary large cell neuroendocrine carcinoma of the urinary bladder.
  • Primary large cell neuroendocrine carcinomas (LCNEC) of the urinary bladder are rare.
  • On cystoscopic examination, a solitary mass measuring 3 cm in diameter was detected protruding from the anterosuperior wall of the urinary bladder.
  • A diagnosis of LCNEC was made based upon histological and immunohistochemical findings.
  • In spite of three cycles of chemotherapy, the patient developed multiple metastases in the lung and liver 10 months postoperatively.
  • LCNEC of the urinary bladder are uncommon entities, which have a possible fatal outcome.
  • [MeSH-major] Carcinoma, Large Cell / secondary. Carcinoma, Neuroendocrine / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystectomy. Hospice Care. Humans. Immunoenzyme Techniques. Male. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17040293.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


7. Davies BJ, Bastacky S, Chung SY: Large cerebellar lesion as original manifestation of transitional cell carcinoma of the bladder. Urology; 2003 Oct;62(4):749
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cerebellar lesion as original manifestation of transitional cell carcinoma of the bladder.
  • Patients with transitional cell carcinoma of the bladder classically present with irritative voiding symptoms or painless hematuria.
  • Vascular metastasis to the brain, without a prior history of chemotherapy, is extremely rare.
  • To our knowledge, this is the first report of a patient with bladder transitional cell carcinoma whose original presentation was from a symptomatic, metastatic, cerebellar lesion.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Cerebellar Neoplasms / secondary. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Ataxia / etiology. Cisplatin / administration & dosage. Combined Modality Therapy. Craniotomy. Cystectomy. Doxorubicin / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Radiosurgery. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14550465.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


8. Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR: A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res; 2001 Sep 1;61(17):6428-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
  • Hepatocellular carcinoma (HCC) is the third leading cause of cancer death in the world.
  • Tumor resection remains the only curative treatment but is often not possible because of advanced stage and frequently unsuccessful because of intrahepatic or distant tumor recurrence. alpha-Fetoprotein (AFP), a tumor marker currently used for the diagnosis and management of HCC, is an oncofetal protein expressed in a majority of HCCs but rarely in normal hepatocytes.
  • In vitro, CV890 expression of the E1A and E1B genes, virus replication, and cytopathic effects were examined by Northern blot, Western blot, virus yield assay, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay in AFP-producing cell lines (HepG2, Huh7, Hep3B, PLC/PRF/5, and SNU449), non-AFP-producing cell lines (Sk-Hep-1, Chang liver cell, LNCaP, HBL-100, PA-1, UM-UC-3, SW 780, Colo 201, and U118 MG), and non-AFP-producing human primary cells (lung fibroblast, bladder smooth muscle, and mammary epithelial).
  • CV890 efficiently replicates in and destroys AFP-producing HCC cells as well as wild-type Ad5, but replication is highly attenuated in non-AFP-producing HCC cells or non-HCC cells.
  • CV890 produced 5,000-100,000-fold less virus than wild-type Ad5 in non-AFP-producing cells.
  • In vivo, antitumor efficacy of CV890 was examined in BALB/c-nu/nu mice containing large s.c.
  • Our results support the clinical development of CV890 as an antineoplastic agent for the treatment of localized or metastatic HCC.
  • [MeSH-major] Adenoviridae / physiology. Antibiotics, Antineoplastic / pharmacology. Carcinoma, Hepatocellular / therapy. Doxorubicin / pharmacology. Liver Neoplasms / therapy
  • [MeSH-minor] Adenovirus E1A Proteins / genetics. Adenovirus E1B Proteins / genetics. Adenovirus E3 Proteins / genetics. Animals. Combined Modality Therapy. Cytopathogenic Effect, Viral. Genetic Vectors. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / therapy. Prostatic Neoplasms / virology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Response Elements / genetics. Ribosomes / genetics. Ribosomes / metabolism. Tumor Cells, Cultured. Virus Replication. Xenograft Model Antitumor Assays. alpha-Fetoproteins / biosynthesis. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11522637.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenovirus E1A Proteins; 0 / Adenovirus E1B Proteins; 0 / Adenovirus E3 Proteins; 0 / Antibiotics, Antineoplastic; 0 / RNA, Messenger; 0 / alpha-Fetoproteins; 80168379AG / Doxorubicin
  •  go-up   go-down


9. Church DN, Bahl A: Clinical review - small cell carcinoma of the bladder. Cancer Treat Rev; 2006 Dec;32(8):588-93
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical review - small cell carcinoma of the bladder.
  • OBJECTIVES: To review the published literature on the diagnosis and management of small cell carcinoma of the bladder (SCCB).
  • METHODS: Papers were identified by searches of PubMed using the terms "small cell", "bladder" and "carcinoma".
  • RESULTS: SCCB comprises less than 1% of bladder malignancies.
  • Consequently, patients are often not fit for anti-neoplastic therapy.
  • In fit patients, the bedrock of treatment in the majority of cases is platinum-based systemic chemotherapy, which was the only factor predictive of improved outcome on multivariate analysis in one large review.
  • The use of neoadjuvant chemotherapy has been associated with favourable results and may therefore be the preferred approach when scheduling treatment.
  • Options for local management comprise surgery or radiotherapy (sequentially or concurrently with chemotherapy), both of which are potentially curative in selected cases.
  • However, the subsequent frequent development of urothelial malignancies with bladder-sparing approaches should be considered when planning treatment, particularly in younger patients.
  • Future efforts should be directed at its early detection and the development of more effective systemic therapies.
  • [MeSH-major] Carcinoma, Small Cell / mortality. Carcinoma, Small Cell / therapy. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Combined Modality Therapy. Humans. Neoadjuvant Therapy. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17008012.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 67
  •  go-up   go-down


10. Kruslin B, Stanić G, Belicza M, Cupić H, Begić-Fehir J, Muić B, Markoja I: [Carcinoma of the urinary bladder resembling lymphoepithelioma]. Lijec Vjesn; 2000 Nov-Dec;122(11-12):270-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinoma of the urinary bladder resembling lymphoepithelioma].
  • Lymphoepithelioma-like carcinoma of the bladder is rare and has only recently been described at this site.
  • We report a case of lymphoepithelioma-like carcinoma of the urinary bladder in a 70-years old male patient who presented with painless hematuria lasting for one month.
  • The patient underwent transurethral resection two times.
  • Histopathologic diagnosis was transitional cell carcinoma.
  • Histopathologic examination of the third biopsy showed tumor tissue with typical syncitial growth pattern of atypical, large, epitheloid cells with ill-defined cytoplasmic borders, prominent nucleoli and numerous mitoses.
  • After last surgery the patient underwent chemotherapy by local application of Adriablastine.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Transitional Cell / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11291269.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


11. Gómez-Román JJ, Cobo ML, Val-Bernal JF: Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting as a bladder neoplasm. Pathol Int; 2008 Apr;58(4):249-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting as a bladder neoplasm.
  • Malignant lymphoma presenting in the bladder has been classified in primary cases, as the first sign of disseminated disease and as a secondary infiltration.
  • Reported herein is the case of a 45-year-old man with an anaplastic large cell lymphoma (anaplastic lymphoma kinase (ALK) and granzyme B positive) that presented as a bladder neoplasm.
  • The morphological differential diagnosis was complex because the EMA-positive immunophenotype, CD45 and CD3 negativity and the clinical manifestation simulated a transitional cell carcinoma.
  • It is important to be aware of its existence because a poorly differentiated bladder carcinoma cannot be ruled out if CD30 and ALK immunostaining are not performed.
  • T-cell receptor-gamma clonal rearrangement could be also helpful in these cases.
  • Although bladder involvement by recurrent lymphoma is a sign of widely disseminated disease and it is associated with a very poor prognosis, it seems that chemotherapeutic regimens in this kind of ALK-positive lymphoma could be effective, given that the present patient had an impressive response to chemotherapy treatment.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Protein-Tyrosine Kinases / metabolism. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Antigens, CD30 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Diagnosis, Differential. Disease-Free Survival. Etoposide / administration & dosage. Humans. Male. Methylprednisolone / administration & dosage. Middle Aged. Mucin-1 / metabolism. Receptor Protein-Tyrosine Kinases. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324919.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 0 / Mucin-1; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


12. Taniguchi H, Sakagami J, Suzuki N, Hasegawa H, Shinoda M, Tosa M, Baba T, Yasuda H, Kataoka K, Yoshikawa T: Adenoendocrine cell carcinoma of the gallbladder clinically mimicking squamous cell carcinoma. Int J Clin Oncol; 2009 Apr;14(2):167-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoendocrine cell carcinoma of the gallbladder clinically mimicking squamous cell carcinoma.
  • We present the case of a 62-year-old Japanese man whose histological diagnosis was adenoendocrine cell carcinoma of the gallbladder at autopsy, but whose antemortem diagnosis was squamous cell carcinoma.
  • Abdominal computed tomography revealed a large tumor on the gallbladder involving the adjacent liver, colon, and duodenum, with multiple metastases in the greater omentum and paraportal lymph nodes.
  • The serum level of squamous cell carcinoma antigen (SCCA) was high, whereas that of carbohydrate antigen (CA) 19-9, as well as that of carcinoembryonic antigen (CEA) was within the normal range.
  • Due to these clinical features, we first suspected advanced squamous cell carcinoma of the gallbladder.
  • Though tumor regression was achieved and his serum SCCA level normalized after 3 months, the patient rejected additional chemotherapy and died 8 months after the diagnosis.
  • The histopathological findings made by autopsy demonstrated the tumor to be an adenoendocrine cell carcinoma without squamous carcinoma cells.
  • The case is interesting in that the clinical features were similar to those of squamous cell carcinoma of the gallbladder.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Small Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2001 Jan;98(1):53-7 [11201126.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):355-74 [16139391.001]
  • [Cites] Curr Opin Oncol. 2005 May;17(3):218-24 [15818164.001]
  • [Cites] Tumour Biol. 1998;19(6):488-93 [9817978.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1231-5 [17016656.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1769-74 [15505626.001]
  • [Cites] Surg Today. 2006;36(9):849-52 [16937295.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1493-7 [1516000.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(1):97-101 [10982599.001]
  • [Cites] J Surg Oncol. 2007 Feb 1;95(2):129-34 [17262729.001]
  • [Cites] Int J Cancer. 1991 Feb 1;47(3):376-9 [1704354.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1588-93 [11813580.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):572-80 [17594719.001]
  • [Cites] Jpn J Clin Oncol. 2007 Nov;37(11):843-51 [17942578.001]
  • (PMID = 19390950.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Serpins; 0 / squamous cell carcinoma-related antigen
  •  go-up   go-down


13. Shimono C, Suwa K, Sato M, Shirai S, Yamada K, Nakamura Y, Makuuchi M: Large cell neuroendocrine carcinoma of the gallbladder: long survival achieved by multimodal treatment. Int J Clin Oncol; 2009 Aug;14(4):351-5
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell neuroendocrine carcinoma of the gallbladder: long survival achieved by multimodal treatment.
  • Large cell neuroendocrine carcinoma of the gall-bladder is a rare disease in which the prognosis worsens with size.
  • We report a case of large cell neuroendocrine carcinoma of the gallbladder in a 64-year-old woman who presented with a right upper quadrant mass whose longest diameter was 11.5 cm; the mass was initially considered to be unresectable because of probable invasion to the main portal vein and biliary tract.
  • The patient received multi-modal treatment, consisting of intraarterial chemotherapy, three-dimensional radiation therapy, right trisegmentectomy, and gamma-knife irradiation (for brain metastases).
  • She has survived for 69 months since the initial diagnosis and has shown no signs of recurrence at 35 months after the last gamma-knife irradiation for brain metastases.
  • This result suggests that multimodal treatment including surgery, chemotherapy, and radiation therapy achieved a good response and led to long survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Carcinoma, Large Cell / therapy. Carcinoma, Neuroendocrine / therapy. Gallbladder Neoplasms / therapy. Radiosurgery
  • [MeSH-minor] Biopsy. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoplasm Invasiveness. Radiation Dosage. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1986 Nov;110(11):1062-6 [3778122.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):905-14 [9255253.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1424-8 [11023106.001]
  • [Cites] Histopathology. 1991 Aug;19(2):173-6 [1661701.001]
  • [Cites] Am J Surg Pathol. 1989 Apr;13(4):292-302 [2648878.001]
  • [Cites] Hum Pathol. 1986 Jun;17(6):614-20 [2872152.001]
  • [Cites] Mod Pathol. 1998 Oct;11(10):1016-20 [9796733.001]
  • [Cites] Hum Pathol. 1984 Jul;15(7):639-46 [6086490.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1493-7 [1516000.001]
  • [Cites] Am J Clin Oncol. 1989 Apr;12(2):114-7 [2539716.001]
  • [Cites] Surgery. 1991 Oct;110(4):604-10; discussion 610-1 [1718046.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):227-32 [1712661.001]
  • [Cites] Acta Pathol Jpn. 1991 May;41(5):383-5 [1678242.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):529-53 [1709558.001]
  • [Cites] J Surg Oncol. 1999 Jan;70(1):54-9 [9989422.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 Feb;4(1):144-6 [15730940.001]
  • [Cites] Acta Cytol. 1999 May-Jun;43(3):534-6 [10349405.001]
  • [Cites] South Med J. 1990 Apr;83(4):485-6 [2157295.001]
  • (PMID = 19705247.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Gilbert SM, Lee CT: A case of T2 muscle-invasive bladder cancer treated with neoadjuvant chemotherapy. Nat Clin Pract Urol; 2006 Dec;3(12):675-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of T2 muscle-invasive bladder cancer treated with neoadjuvant chemotherapy.
  • Cystoscopic evaluation revealed a large bladder tumor.
  • DIAGNOSIS: High-grade muscle-invasive transitional cell carcinoma (clinical stage T2N0M0, later confirmed as pathologic stage T3aN0M0).
  • MANAGEMENT: Transurethral resection of the bladder tumor, clinical trialbased neoadjuvant treatment with paclitaxel, carboplatin and gemcitabine, and radical cystectomy.
  • [MeSH-major] Carcinoma, Transitional Cell / therapy. Muscle Neoplasms / therapy. Neoadjuvant Therapy / methods. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Invasiveness / diagnosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17149384.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


15. Berglund RK, Savage CJ, Vora KC, Kurta JM, Cronin AM: An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder. J Urol; 2008 Oct;180(4):1297-300; discussion 1300
MedlinePlus Health Information. consumer health - Statins.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
  • PURPOSE: Bacillus Calmette-Guerin is an effective immunotherapy for carcinoma in situ of the bladder and it reduces recurrence from resected papillary transitional cell carcinoma of the bladder.
  • Many patients receiving bacillus Calmette-Guerin therapy are concurrently taking statin agents, which have known immunomodulatory properties and may alter the performance of bacillus Calmette-Guerin.
  • Some data have suggested that patients taking a statin while on bacillus Calmette-Guerin therapy experience reduced clinical efficacy.
  • Time to recurrence and progression to surgery were compared between those taking and those not taking a statin by Kaplan-Meier methods and multivariable Cox regression controlling for stage and grade.
  • RESULTS: There were 245 (26%) patients taking a statin before bacillus Calmette-Guerin therapy and 707 not on statin therapy (74%).
  • Median time to recurrence was similar between those who did and those who did not use a statin.
  • On multivariable analysis statin use was not significantly associated with recurrence (hazard ratio 1.04; 95% CI 0.81, 1.34; p = 0.7) or progression to surgery (hazard ratio 0.77; 95% CI 0.52, 1.13; p = 0.17) after bacillus Calmette-Guerin therapy.
  • CONCLUSIONS: This retrospective study in a large cohort of patients showed no statistically significant association between statin use and recurrence or progression to open surgery in patients treated with bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
  • Based on these data patients should not be discouraged from taking statins while undergoing bacillus Calmette-Guerin treatment.
  • [MeSH-major] BCG Vaccine / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use. Neoplasm Recurrence, Local / diagnosis. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Aged, 80 and over. Cohort Studies. Disease Progression. Drug Therapy, Combination. Evaluation Studies as Topic. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Reference Values. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707737.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  •  go-up   go-down


16. Palou J, Baniel J, Klotz L, Wood D, Cookson M, Lerner S, Horie S, Schoenberg M, Angulo J, Bassi P: Urothelial carcinoma of the prostate. Urology; 2007 Jan;69(1 Suppl):50-61
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urothelial carcinoma of the prostate.
  • This study was conducted to explore the diagnosis and management of urothelial carcinoma of the prostate in superficial disease and carcinoma in situ, stromal invasion, primary urothelial carcinoma, and urethral recurrence after radical surgery.
  • A consensus conference convened by the World Health Organization (WHO) and the Société Internationale d'Urologie (SIU) reviewed the diagnosis and management of urothelial carcinoma of the bladder.
  • English-language literature about urothelial carcinoma of the prostate was identified and reviewed.
  • Evidence-based recommendations for the diagnosis and management of urothelial carcinoma were made.
  • Many recommendations were level 3 or 4 citations involving the diagnosis and management of superficial urothelial carcinoma; a few were level 2 citations.
  • Level 1 citations related only to chemotherapy and radiotherapy in patients with stromal invasion, although these were not related specifically to invasive prostatic involvement.
  • Published reports on the diagnosis and treatment of superficial urothelial disease of the prostate primarily consist of short case series from individual centers.
  • In invasive disease of the prostate, the only large series were designed to investigate invasive bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell. Prostatic Neoplasms
  • [MeSH-minor] Diagnosis, Differential. Global Health. Humans. Incidence. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Prostatectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17280908.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 65
  •  go-up   go-down


17. Kirkali Z, Tuzel E: Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol; 2003 Aug;47(2):155-69
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the ureter and renal pelvis.
  • Transitional cell carcinoma (TCC) of ureter and renal pelvis is relatively uncommon.
  • Approximately 20-50% of patients with upper urinary tract (UUT) TCC have bladder cancer at some point on their course, whereas the incidence of UUT TCC after primary bladder cancer is 0.7-4%.
  • Nephroureterectomy with bladder cuff excision has been the mainstay of treatment.
  • Local resection may be appropriate for distal ureteral lesions especially when the disease is low grade and stage.
  • Adjuvant topical therapies appear to be safe but confirmation of any benefits awaits the results of further large studies.
  • Adjuvant radiotherapy is ineffective, and systemic chemotherapy results in a low complete response rate for patients with metastases.
  • [MeSH-major] Carcinoma, Transitional Cell. Kidney Neoplasms. Ureteral Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Humans. Kidney Pelvis / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / etiology. Urinary Bladder Neoplasms / therapy

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12900009.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 146
  •  go-up   go-down


18. Margulis V, Lotan Y, Shariat SF: Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol; 2008 Feb;26(1):59-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin: a promising biomarker for detection and prognosis of bladder cancer.
  • Survivin is a 16.5 kDa member of the inhibitor of apoptosis protein family that is overexpressed in many malignancies but rarely detected in normal differentiated adult tissues.
  • Functionally, Survivin inhibits apoptosis, promotes cell proliferation, and induces/enhances angiogenesis.
  • In transitional cell carcinoma of the urinary bladder, Survivin has been shown to be a promising biomarker for cancer diagnosis, prognosis and prediction of response to intravesical or systemic therapies.
  • Moreover, in pre-clinical bladder tumor models, inhibition of Survivin expression and/or function has been shown to impede tumor cell proliferation, and markedly induce spontaneous or chemotherapy induced apoptosis.
  • These preliminary findings should now be confirmed in large prospective trials.
  • Furthermore, simplified, quantitative and reproducible assays need to be developed and validated for the detection of Survivin and its different isoforms.
  • [MeSH-major] DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Mass Screening / methods. Microtubule-Associated Proteins / genetics. Neoplasm Proteins / genetics. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7724-32 [14633697.001]
  • [Cites] Lancet Oncol. 2007 Feb;8(2):128-36 [17267327.001]
  • [Cites] J Cell Physiol. 2006 Sep;208(3):476-86 [16557517.001]
  • [Cites] Mol Cell. 2000 Aug;6(2):211-23 [10983970.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4407-14 [17671123.001]
  • [Cites] World J Urol. 1997;15(2):84-8 [9144896.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):631-5 [14713775.001]
  • [Cites] J Cell Biochem. 2004 Jul 1;92(4):656-63 [15211564.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):1994-2007 [15688031.001]
  • [Cites] J Urol. 2003 Jul;170(1):230-4 [12796695.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):626-30 [14713774.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2007 Feb 6;87(6):419-22 [17456386.001]
  • [Cites] Genes Dev. 1999 Feb 1;13(3):239-52 [9990849.001]
  • [Cites] Int J Oncol. 2004 Oct;25(4):1065-71 [15375557.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):100-4 [15761870.001]
  • [Cites] Ann Oncol. 2003 Jan;14(1):85-90 [12488298.001]
  • [Cites] Clin Chem. 2004 Aug;50(8):1425-8 [15277352.001]
  • [Cites] Urology. 1998 Sep;52(3):398-402 [9730450.001]
  • [Cites] J Urol. 2005 Nov;174(5):2046-50 [16217391.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] Adv Exp Med Biol. 2003;539(Pt A):111-9 [15088900.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2683-92 [12855648.001]
  • [Cites] JAMA. 2001 Jan 17;285(3):324-8 [11176843.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1106-13 [17311310.001]
  • [Cites] Int J Oncol. 2007 Jun;30(6):1317-24 [17487351.001]
  • [Cites] J Urol. 2006 Jun;175(6):2312-6 [16697865.001]
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):49-60 [17275177.001]
  • [Cites] N Engl J Med. 1999 Aug 5;341(6):452-3 [10438269.001]
  • [Cites] Urology. 2007 Sep;70(3):482-6 [17905101.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2026-32 [11391581.001]
  • [Cites] Pharmacoeconomics. 2003;21(18):1315-30 [14750899.001]
  • [Cites] J Urol. 2006 Dec;176(6 Pt 1):2414-22; discussion 2422 [17085118.001]
  • [Cites] Cancer Lett. 2006 Feb 8;232(2):243-54 [16458121.001]
  • [Cites] Chin Med J (Engl). 2006 Oct 20;119(20):1734-9 [17097022.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):263-70 [15375012.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Aug;130(8):487-90 [15138808.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2462-7 [11980633.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Jun;10(2):134-8 [12051631.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Tumour Biol. 2007;28(2):57-62 [17259754.001]
  • [Cites] Oncogene. 2007 Nov 29;26(54):7569-75 [17546047.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):46-54 [12509766.001]
  • (PMID = 17962949.001).
  • [ISSN] 0724-4983
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  • [Number-of-references] 42
  •  go-up   go-down


19. Hasegawa H, Kuzushita N, Nakazuru S, Itoh M, Araki M, Yoshioka C, Suemura S, Ohta M, Yoshio T, Toyama T, Ikura Y, Mita E: [Case of primary hepatic neuroendocrine carcinoma diagnosed by needle biopsy]. Nihon Shokakibyo Gakkai Zasshi; 2010 Dec;107(12):1956-62
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of primary hepatic neuroendocrine carcinoma diagnosed by needle biopsy].
  • The patient was a 55-year-old man with a large hepatic tumor measuring 12 × 12 cm in the left lobe.
  • To obtain the histological diagnosis, the target liver biopsy was performed.
  • Histologically, the tumor revealed as a neuroendocrine carcinoma.
  • After the diagnosis, he received the chemotherapy (CTX) with etoposide and cisplatin.
  • We here report a case of primary hepatic neuroendocrine carcinoma treated with CTX following the diagnosis by the needle biopsy.
  • [MeSH-major] Biopsy, Needle. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / pathology. Liver / pathology. Liver Neoplasms / diagnosis. Liver Neoplasms / pathology. Neoplasms, Multiple Primary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell. Cisplatin / administration & dosage. Diagnosis, Differential. Diagnostic Imaging. Etoposide / administration & dosage. Humans. Male. Middle Aged. Urinary Bladder Neoplasms

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139365.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Siefker-Radtke A: Urachal carcinoma: surgical and chemotherapeutic options. Expert Rev Anticancer Ther; 2006 Dec;6(12):1715-21
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urachal carcinoma: surgical and chemotherapeutic options.
  • The urachal ligament is an embryologic remnant connecting the dome of the bladder to the umbilicus via the ligamentum commune.
  • Patients usually present with hematuria and upon imaging, have evidence of a cystic or solid structure in the bladder dome or in the bladder midline.
  • Although there are no prospective clinical trials reported to date, large single-institution reports suggest surgical resection with a partial cystectomy and en bloc resection of the urachal ligament with umbilicus as the treatment of choice in the setting of localized disease.
  • Although there is currently no definitive role for neoadjuvant or adjuvant chemotherapy in this tumor, risk factors predicting progression may allow for the selection of patients at higher relapse risk for prospective studies.
  • There is no standard chemotherapy regimen for these patients; however, there is new-found hope with a currently accruing clinical trial exploring a 5-fluorouracil-based chemotherapy combination in this patient population.
  • [MeSH-major] Adenocarcinoma / therapy. Cystectomy / methods. Urachus / pathology. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / pathology. Cisplatin / administration & dosage. Clinical Trials as Topic. Clinical Trials, Phase II as Topic. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Hematuria / etiology. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Risk Factors. Umbilicus / surgery. Urachal Cyst / pathology. Urachal Cyst / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17181485.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 29
  •  go-up   go-down


21. Mohile SG, Schleicher L, Petrylak DP: Treatment of metastatic urachal carcinoma in an elderly woman. Nat Clin Pract Oncol; 2008 Jan;5(1):55-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic urachal carcinoma in an elderly woman.
  • Imaging revealed a large pelvic mass situated on the dome of the bladder, extending from the urachus, without evidence of other sites of metastases.
  • No adjuvant therapy was administered.
  • Repeat imaging obtained 3 months after resection revealed a large left pelvic mass consistent with recurrence.
  • DIAGNOSIS: Metastatic urachal adenocarcinoma.
  • MANAGEMENT: Surgical excision combined with cystectomy and pelvic lympadenectomy, chemotherapy with 5-fluorouracil, leucovorin, and irinotecan.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / secondary. Cystectomy. Lymph Node Excision. Pelvic Neoplasms / secondary. Urachus. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097457.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


22. Chong JT, Mick A: Choroidal metastasis: case reports and review of the literature. Optometry; 2005 May;76(5):293-301
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Their diagnosis has become more common due to increased emphasis on comprehensive eye examinations for cancer patients and the improved life expectancy of patients with metastatic disease.
  • METHODS: A thorough fundus examination, coupled with the use of A-scan and B-scan ultrasonography, will aid in their diagnosis.
  • There are many ways of treating these tumors, including radiation therapy, chemotherapy, and monitoring.
  • Case 1 involved a patient with lung cancer who manifested a large bullous exudative retinal detachment due to an underlying choroidal metastasis.
  • Case 2 dealt with treatment of a patient with metastatic transitional cell cancer who manifested a shallow exudative retinal detachment caused by a choroidal metastasis.
  • CONCLUSIONS: Due to progress of chemotherapeutic medications, the number of patients who manifest choroidal metastases will continue to increase.
  • It is essential for the practitioner to be able to recognize this disease process to prevent visual loss and institute referral for proper treatment for metastatic disease.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Choroid Neoplasms / secondary. Lung Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Disease Progression. Humans. Incidence. Magnetic Resonance Imaging. Male. Middle Aged. Retinal Detachment / diagnosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15884419.001).
  • [ISSN] 1529-1839
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Zetola-Burneo N, Brown C: Cases from the Osler Medical Service at Johns Hopkins University. Am J Med; 2004 Feb 1;116(3):198-200
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 47-year-old white woman with a history of stage III squamous cell carcinoma of the anus was transferred to Johns Hopkins Hospital for further evaluation of renal failure, hemolytic anemia, and thrombocytopenia.
  • The patient was first diagnosed with squamous cell carcinoma of the anus 1 year before admission.
  • She was treated with external beam radiation of the pelvis and two cycles of mitomycin C-based chemotherapy (a cumulative dose, 34 mg/m(2)).
  • Three months before admission, the patient developed dysuria.
  • One month before admission, she underwent a cystoscopy, which showed only radiation-induced changes in the bladder.
  • Laboratory data showed a white blood cell count of 6390/mm(3), a hematocrit level of 26.5%, and a platelet count of 26,000/mm(3).
  • Urinalysis showed innumerable red blood cells and large protein.
  • There was no radiographic or clinical evidence of relapse of her squamous cell carcinoma.
  • What is the diagnosis?
  • [MeSH-minor] Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14749166.001).
  • [ISSN] 0002-9343
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


24. Nettesheim O, Höffken G, Gahr M, Breidert M: [Haematemesis and dysphagia in a 20-year-old woman with congenital spine malformation and situs inversus partialis]. Z Gastroenterol; 2003 Apr;41(4):319-24
Hazardous Substances Data Bank. PHENOXYBENZAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hämatemesis und Dysphagie bei 20 Jahre alter Frau mit kongenitalem kaudalen Regressionssyndrom und Situs inversus partialis.
  • Bladder function disorders were present since childhood.
  • Upper endoscopy demonstrated a 4 cm large, exophytically growing necrotic tumour of the oesophagus.
  • Histology of the tumour biopsies showed a poor differentiated squamous cell carcinoma.
  • Staging after the 6 th dose cisplatin (100 mg/m2/die) and 5-fluorouracil (5 x 1000 mg/m2/die) showed a mild reduction of the tumour and the metastases.
  • The manifestation of squamous cell carcinoma of the oesophagus is unusual in people at the age of twenty.
  • Drug history revealed that the patient had been treated with the alpha-receptor blocking drug phenoxybenzamine over at least 12 years for bladder dysfunction.
  • By the German admission board phenoxybenzamine is only recommended for short term therapy.
  • It seems to be likely that even in humans phenoxybenzamine acts as a mutagenic substance and should be carefully used in long-term treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Deglutition Disorders / etiology. Esophageal Neoplasms / diagnosis. Hematemesis / etiology. Kyphosis / congenital. Lung Neoplasms / secondary. Neural Tube Defects / diagnosis. Scoliosis / congenital. Situs Inversus / diagnosis. Spina Bifida Occulta / diagnosis
  • [MeSH-minor] Adrenergic alpha-Antagonists / adverse effects. Adrenergic alpha-Antagonists / therapeutic use. Adult. Biopsy. Esophagus / pathology. Female. Humans. Long-Term Care. Neoplasm Staging. Phenoxybenzamine / administration & dosage. Phenoxybenzamine / adverse effects. Urinary Bladder, Neurogenic / congenital. Urinary Bladder, Neurogenic / drug therapy


25. Karakiewicz PI, Benayoun S, Lewinshtein DJ, Chun FK, Shahrour K, Perrotte P: Treatment of BCG failures with intravesical BCG/Interferon: the University of Montreal experience. Can J Urol; 2006 Aug;13(4):3189-94
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of BCG failures with intravesical BCG/Interferon: the University of Montreal experience.
  • OBJECTIVE: Bacillus Calmette-Guerin (BCG) has shown promise in large scale studies.
  • We assessed recurrence-free survival in patients treated with intravesical BCG/Interferon (IFN) for non-muscle invasive, BCG refractory, transitional cell carcinoma (TCC) of the urinary bladder at our local institution.
  • Select patients were treated with BCG/Interferon maintenance therapy.
  • Stages at TCC diagnosis were distributed as follows: 6 (46%) CIS, 3 (23%) Ta, and 4 (31%) T1.
  • In selected patients, intravesical BCG/IFN offers a valid alternative to definitive therapy.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Antineoplastic Agents / administration & dosage. BCG Vaccine / administration & dosage. Carcinoma, Transitional Cell / drug therapy. Interferons / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Aged, 80 and over. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952327.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents; 0 / BCG Vaccine; 9008-11-1 / Interferons
  •  go-up   go-down


26. Marnitz S, Köhler C, Füller J, Hinkelbein W, Schneider A: Uterus necrosis after radiochemotherapy in two patients with advanced cervical cancer. Strahlenther Onkol; 2006 Jan;182(1):45-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A large body of literature concerning therapy-related acute and late morbidity is available.
  • Both patients were diagnosed with squamous cell cancer of the cervix FIGO stage IIB (T2b pN1 pM1 LYM G2) and FIGO IIIA (T3a pN1 M0 G2), respectively.
  • Patient #2 underwent 5 x 5 Gy brachytherapy covering the tumor.
  • Following chemoradiation, both patients developed pelvic pain and an elevation of C-reactive protein (CRP) in the presence of a normal leukocyte count.
  • Both patients underwent relaparoscopy, and necrosis of the uterus combined with partial necrosis of the bladder was diagnosed in patient #1.
  • CONCLUSION: In patients with persisting or incident pelvic pain, questionable findings in imaging techniques and/or elevated inflammation parameters following completion of chemoradiation for cervical cancer, differential diagnosis should include radiogenic necrosis of the uterus and other pelvic organs.
  • Laparoscopy is an ideal technique to exclude or confirm this diagnosis.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Radiation Injuries / etiology. Radiotherapy / adverse effects. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy. Uterus / pathology. Uterus / radiation effects
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Brachytherapy. Cervix Uteri / pathology. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Hysterectomy. Iridium Radioisotopes / therapeutic use. Laparoscopy. Middle Aged. Necrosis. Neoplasm Staging. Ovariectomy. Radiotherapy Dosage. Radiotherapy, Conformal. Time Factors






Advertisement